CIM Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

CIM Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$310K	Buy	+12,537	New	+$299K	0.08%	191
2025 Q2	–	Sell	-8,593	Closed	-$208K	–	254
2025 Q1	$208K	Buy	+8,593	New	+$194K	0.05%	214
2024 Q2	–	Sell	-10,888	Closed	-$174K	–	264
2024 Q1	$174K	Hold	10,888	–	–	0.05%	264
2023 Q4	$183K	Hold	10,888	–	–	0.06%	270
2023 Q3	$127K	Hold	10,888	–	–	0.05%	266
2023 Q2	$146K	Buy	+10,888	New	+$157K	0.05%	261

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

CIM Investment Management's CPRX Position: Q1 2026 in Review

CIM Investment Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 12,537 shares worth $310K. The stake represents 0.08% of the portfolio and ranks #191 among its holdings. This is a return to the name: CIM Investment Management previously reported a position in CPRX as recently as Q1 2025.

CIM Investment Management first reported a position in CPRX in Q2 2023 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

CIM Investment Management held 12,537 shares of Catalyst Pharmaceutical worth $310K as of Q1 2026.
Catalyst Pharmaceutical was a new CIM Investment Management position in Q1 2026.
Catalyst Pharmaceutical made up 0.08% of CIM Investment Management's portfolio in Q1 2026, its #191 holding.
CIM Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 6 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.